AI Assistant
Blog
Pricing
Log In
Sign Up
Breakthrough COVID-19 is mild in vaccinated patients with hematological malignancy receiving tixagevimab-cilgavimab as pre-exposure prophylaxis
Details
Cite
Export
Add to List
This content is not available in your region!
Continue researching
here.